Ticker Details
Nektar Therapeutics Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain.
IPO Date:	May 3, 1994
Sector:	Healthcare
Industry:	Pharma
Market Cap:	$2.53B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.47 | 2.88%
Avg Daily Range (30 D):	$1.18 | 1.66%
Avg Daily Range (90 D):	$1.85 | 2.51%

Institutional Daily Volume
Avg Daily Volume:	1.47M
Avg Daily Volume (30 D):	.54M
Avg Daily Volume (90 D):	.82M

Trade Size
Avg Trade Size (Sh.):	161
Avg Trade Size (Sh.) (30 D):	46
Avg Trade Size (Sh.) (90 D):	52

Institutional Trades
Total Institutional Trades:	9,604
Avg Institutional Trade:	$2.75M
Avg Institutional Trade (30 D):	$3.97M
Avg Institutional Trade (90 D):	$5.02M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.02M
Avg Closing Trade (30 D):	$6.57M
Avg Closing Trade (90 D):	$9.43M
Avg Closing Volume:	22.75K

News

May 23, 2026 @ 8:28 PM What to Know About This Fund's $10 Million Nektar ... Source: Jonathan Ponciano

May 5, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Nektar The... Source: Bronstein, Gewirtz & Grossman Llc

May 5, 2026 @ 12:23 AM NKTR Investor Alert: Nektar Therapeutics Securitie... Source: Levi & Korsinsky, Llp

May 4, 2026 @ 10:57 PM NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar ... Source: Bragar Eagel & Squire, P.C.

May 4, 2026 @ 1:38 AM NKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIG... Source: Rosen Law Firm

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-6.51	$-1.23	$-1.82
Diluted EPS	$-6.51	$-1.23	$-1.82
Revenue	$54.59M	$10.13M	$10.86M
Gross Profit
Net Income / Loss	$-157.13M	$-40.62M	$-44.9M
Operating Income / Loss	$-140.73M	$-42.34M	$-39.05M
Cost of Revenue
Net Cash Flow	$-3.72M	$-110.31M	$134.46M
PE Ratio

Splits
Jun 09, 2025	1:15
Aug 23, 2000	2:1